SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
AstraZeneca PLC Dives Deeper Into Personalized Medicine With Abbott, Montreal Heart Institute Deals
May 13, 2015
 · 
3 min read
Business
Startup Surface Oncology Brings in Ex-AstraZeneca PLC Exec to Lead Next-Gen Immuno-Oncology Plan
May 7, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
White-Hot Flagship Ventures Inks Deals With AstraZeneca PLC, Bayer CropScience AG and Nestle SA As VC Roars
May 5, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Policy
Texas Psychiatrists Accused of Accepting Bribes from AstraZeneca PLC to Manipulate State Formulary
April 24, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Innate Pharma Strikes Cancer Pact Worth $1.275 Billion With Pharma Giant AstraZeneca PLC
April 24, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Celgene Slaps Down $450 Million Upfront for AstraZeneca PLC’s Prized Immunotherapy Blood Cancer Drug
April 24, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Rumors Swirl Pfizer Will Bid for AstraZeneca PLC Again
April 22, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC’s Experimental Lung Cancer Drug Delays Disease By More Than a Year
April 17, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
FDA Panel Wants Heart Risk Warnings for AstraZeneca PLC, Takeda Diabetes Drugs
April 15, 2015
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Load More